Thompson Peter A.'s most recent trade in Sionna Therapeutics Inc. was a trade of 29,063 Common Stock done at an average price of $44.6 . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.58 per share. | 02 Feb 2026 | 29,063 | 3,530,702 | - | 44.6 | 1,295,629 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.57 per share. | 02 Feb 2026 | 1,890 | 3,559,765 | - | 44.6 | 84,237 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.00 per share. | 28 Jan 2026 | 30,000 | 30,000 (0%) | 0% | 15 | 450,000 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.70 per share. | 28 Jan 2026 | 15,000 | 45,000 (0%) | 0% | 9.7 | 145,500 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.50 per share. | 28 Jan 2026 | 15,000 | 60,000 (0%) | 0% | 12.5 | 187,500 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.61 per share. | 28 Jan 2026 | 15,000 | 75,000 (0%) | 0% | 3.6 | 54,150 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 28 Jan 2026 | 15,000 | 90,000 (0%) | 0% | 2 | 30,000 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.27 per share. | 28 Jan 2026 | 15,000 | 105,000 (0%) | 0% | 3.3 | 49,050 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.74 per share. | 28 Jan 2026 | 15,000 | 120,000 (0%) | 0% | 2.7 | 41,100 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 28 Jan 2026 | 15,000 | 135,000 (0%) | 0% | 2.6 | 39,000 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 28 Jan 2026 | 15,000 | 150,000 (0%) | 0% | 1.0 | 14,849 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.96 per share. | 28 Jan 2026 | 15,000 | 165,000 (0%) | 0% | 1.0 | 14,475 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.49 per share. | 28 Jan 2026 | 15,000 | 180,000 (0%) | 0% | 2.5 | 37,350 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 28 Jan 2026 | 15,000 | 195,000 (0%) | 0% | 1.6 | 24,600 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.12 per share. | 28 Jan 2026 | 15,000 | 210,000 (0%) | 0% | 2.1 | 31,800 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.55 per share. | 24 Dec 2025 | 33,356 | 3,561,655 | - | 44.6 | 1,486,010 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 17 Dec 2025 | 900 | 3,595,986 | - | 44.5 | 40,050 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.49 per share. | 17 Dec 2025 | 875 | 3,595,011 | - | 44.5 | 38,929 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.49 per share. | 17 Dec 2025 | 100 | 3,595,886 | - | 44.5 | 4,449 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.54 per share. | 24 Nov 2025 | 94,583 | 3,610,376 | - | 44.5 | 4,212,727 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.60 per share. | 24 Nov 2025 | 11,890 | 3,598,486 | - | 44.6 | 530,294 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 44.49 per share. | 24 Nov 2025 | 1,600 | 3,596,886 | - | 44.5 | 71,184 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | 27 Jun 2025 | 1,397,684 | 0 | - | - | Common Warrants (right to buy) | ||
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | 27 Jun 2025 | 1,397,684 | 8,341,338 (27%) | 4% | 3.5 | 4,891,894 | Common Stock | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 4.16 per share. | 27 Jun 2025 | 1,176,332 | 7,165,006 (23%) | 3% | 4.2 | 4,891,894 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 20.13 per share. | 03 Apr 2025 | 372,578 | 14,809,075 | - | 20.1 | 7,499,995 | Common Stock |
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 20.13 per share. | 03 Apr 2025 | 124,193 | 443,792 | - | 20.1 | 2,500,005 | Common Stock |
| Sionna Therapeutics Inc | Peter A. Thompson | Director | 10 Feb 2025 | 3,154,959 | 3,154,959 | - | - | Common Stock | ||
| Sionna Therapeutics Inc | Peter A. Thompson | Director | 10 Feb 2025 | 2,560,951 | 0 | - | - | Series B convertible preferred stock | ||
| Sionna Therapeutics Inc | Peter A. Thompson | Director | 10 Feb 2025 | 2,048,760 | 0 | - | - | Series C convertible preferred stock | ||
| Sionna Therapeutics Inc | Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 10 Feb 2025 | 550,000 | 3,704,959 | - | 18 | 9,900,000 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 26 Aug 2024 | 83,695 | 0 | - | 13 | 1,088,035 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 21 Aug 2024 | 394,400 | 557,977 | - | 13.5 | 5,332,288 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 21 Aug 2024 | 391,482 | 153,195 | - | 12.9 | 5,065,777 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 13.03 per share. | 21 Aug 2024 | 69,500 | 83,695 | - | 13.0 | 905,585 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 14.61 per share. | 21 Aug 2024 | 13,300 | 544,677 | - | 14.6 | 194,313 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 20,594 | 20,594 | - | - | Stock Options (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | 18 May 2024 | 2,416,181 | 0 (0%) | 12% | - | Common Stock | ||
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | 18 May 2024 | 264,315 | 0 (0%) | 1% | - | Common Stock | ||
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 17,500 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 May 2024 | 1,444,085 | 1,444,085 | - | - | Pre-Funded Warrants (right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 May 2024 | 1,397,684 | 1,397,684 | - | - | Common Warrants (right to buy) | |
| Edgewise Therapeutics Inc | Thompson Peter A. | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 11.00 per share. | 23 Jan 2024 | 454,545 | 14,436,497 | - | 11 | 4,999,995 | Common Stock |
| Alpine Immune Sciences Inc | A. Peter Thompson | Director | 11 Jan 2024 | 145,251 | 0 | - | - | Warrant (Right to Buy) | ||
| Alpine Immune Sciences Inc | A. Peter Thompson | Director | 11 Jan 2024 | 145,251 | 2,416,181 (12%) | 0% | 12.7 | 1,850,498 | Common Stock | |
| Alpine Immune Sciences Inc | A. Peter Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Thompson A. Peter | Director | Sale of securities on an exchange or to another person at price $ 18.32 per share. | 27 Dec 2023 | 1,195,683 | 2,270,930 (12%) | 6% | 18.3 | 21,904,913 | Common Stock |
| Alpine Immune Sciences Inc | Peter Thompson A. | Director | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 27 Dec 2023 | 162,576 | 3,493,485 (18%) | 0% | 20.0 | 3,245,017 | Common Stock |
| Alpine Immune Sciences Inc | Thompson Peter A. | Director | Sale of securities on an exchange or to another person at price $ 18.32 per share. | 27 Dec 2023 | 139,166 | 264,315 (1%) | 0% | 18.3 | 2,549,521 | Common Stock |
| Alpine Immune Sciences Inc | Thompson A. Peter | Director | Sale of securities on an exchange or to another person at price $ 19.82 per share. | 27 Dec 2023 | 26,872 | 3,466,613 (18%) | 0% | 19.8 | 532,603 | Common Stock |
| Alpine Immune Sciences Inc | Thompson A. Peter | Director | Sale of securities on an exchange or to another person at price $ 19.96 per share. | 27 Dec 2023 | 18,922 | 406,609 (2%) | 0% | 20.0 | 377,683 | Common Stock |
| Alpine Immune Sciences Inc | A. Thompson Peter | Director | Sale of securities on an exchange or to another person at price $ 19.82 per share. | 27 Dec 2023 | 3,128 | 403,481 (2%) | 0% | 19.8 | 61,997 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| ARS Pharma Inc | Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 6.20 per share. | 29 Aug 2023 | 500,000 | 8,019,187 | - | 6.2 | 3,100,000 | Common Stock |
| ARS Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Decibel Therapeutics Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 29 Dec 2021 | 36,700 | 2,258,566 | - | 20.3 | 745,010 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 29 Dec 2021 | 3,700 | 231,098 | - | 20.3 | 75,110 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 21 Dec 2021 | 108,300 | 2,295,266 | - | 19 | 2,057,700 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 21 Dec 2021 | 11,100 | 234,798 | - | 19 | 210,900 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.07 per share. | 16 Dec 2021 | 356,800 | 2,403,566 | - | 19.1 | 6,804,176 | Common Stock |
| Janux Therapeutics Inc | Peter A. Thompson | Director | Sale of securities on an exchange or to another person at price $ 19.07 per share. | 16 Dec 2021 | 36,500 | 245,898 | - | 19.1 | 696,055 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 20 Sep 2021 | 1,109,644 | 6,943,654 (22%) | 3% | 6.1 | 6,757,732 | Common Stock, $0.0001 par value |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.40 per share. | 17 Sep 2021 | 585,106 | 3,656,061 (19%) | 3% | 9.4 | 5,499,996 | Common Stock |
| Alpine Immune Sciences Inc | Peter A. Thompson | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.40 per share. | 17 Sep 2021 | 425,531 | 425,531 (2%) | 2% | 9.4 | 3,999,991 | Common Stock |
| Corvus Pharma Inc | Peter A. Thompson | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 1,348,421 | 1,348,421 | - | - | Common Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 1,052,632 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 823,742 | 2,172,163 | - | - | Common Stock | ||
| Janux Therapeutics Inc | Peter A. Thompson | Director | 15 Jun 2021 | 643,046 | 0 | - | - | Series B Convertible Preferred Stock |